UDP-glucuronosyltransferase 2B7

BE0003679ProteinHumansUGT2B7

UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:10702251, PubMed:15231852, PubMed:15470161,... It is acted on by 95 drugs in DrugBank.

Gene name
UGT2B7
UniProtKB entry
P16662Swiss-Prot
Cellular location
Endoplasmic reticulum membrane
Residues / weight
529 residues · 60,720 Da
Also known as
2.4.1.17 · 3,4-catechol estrogen-specific UDPGT · UDP-glucuronosyltransferase 2B9 · UDPGT 2B7 · UDPGT 2B9

Resolves to

Protein
UniProtP16662UniProt nameUD2B7_HUMAN
Gene
HGNCHGNC:12554NCBI Gene7364GenBank340080GeneCardsUGT2B7
Pharmacology
KEGGhsa:7364
Structure
PDB2O6L
Drugs

What you can answer from here — as of September 07, 2019

95DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
4Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
78Metabolic reactionsDrug transformations it catalyses, substrate to product
Sign in
4GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
157+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on UDP-glucuronosyltransferase 2B7, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In